Biphasic Lipid Vesicles Stabilizing Interferon Alpha-2b
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biphasic lipid-vesicle compositions for treating cervical dysplasia have a limited shelf-life, necessitating the development of improved formulations that enhance the stability and longevity of interferon alpha-2b.
Innovation Solution
Incorporating pharmaceutically acceptable salts of arginine and a water-soluble antioxidant like methionine into the biphasic lipid vesicle compositions, which synergistically interact with interferon alpha-2b to reduce aggregation and extend the shelf-life, while maintaining biological potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a water-soluble antioxidant like methionine is used to stabilize interferon, then oxidative stabilization is improved, but shelf-life is limited
Solution Approach 1:
The invention combines multiple stabilizing agents (methionine antioxidant, arginine salt, and sucrose) within the liposome formulation to create a composite stabilization system that addresses both oxidative degradation and aggregation, thereby extending shelf-life beyond what a single agent could achieve
Solution Approach 2:
The invention optimizes the concentrations of multiple components (0.01-5% methionine, 0.01-0.5% arginine salt, 1-10% sucrose) to achieve enhanced stability and extended shelf-life through synergistic interactions among the stabilizing agents
2Reliability
If interferon alpha-2b is formulated in biphasic lipid vesicles for treating cervical dysplasia, then therapeutic effectiveness is improved, but shelf-life is reduced
Solution Approach 1:
The formulation integrates interferon alpha-2b within liposomes containing a composite stabilization system (methionine, arginine salt, and sucrose), creating a multi-component formulation that maintains therapeutic effectiveness while extending shelf-life to at least 18 months
Solution Approach 2:
The liposome structure acts as an intermediary vehicle that protects interferon alpha-2b from degradation while maintaining its biological activity, and the combined stabilizing agents within the liposome further protect the interferon during storage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions exhibit enhanced stability, retaining at least 60% of labeled interferon activity over 24 months and extending the shelf-life to at least 18 months when stored under refrigerated conditions, significantly improving the stability and usability of the treatment.
Implementation Method 1
The interferon in both phases is oxidatively stabilized by the addition of methionine which unexpectedly partitions preferentially into the aqueous portion of the emulsion
Implementation Method 2
arginine stabilizes interferon alpha-2b by reducing the rate of formation of aggregates
Implementation Method 3
a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b
Data Source
AI summary
This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.